Antigen Discovery Wins $3.1M from NIAID for Work on Malaria Markers, Microfluidic Dx Device | GenomeWeb

Proteomics firm Antigen Discovery said this week that it has received two Small Business Innovation Research awards totaling roughly $3.1 million for work on protein biomarkers for malaria and an integrated microfluidic point-of-care diagnostic device.

The malaria biomarker award is a three-year, Phase II SBIR grant from the National Institute of Allergy and Infectious Disease totaling $2.5 million. The microfluidic device award is a Phase I SBIR grant, also from the NIAID, totaling $600,000.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.